A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P
A phase 2 trial of Gemcitabine, Nogapendekin alfa inbakicept in ovarian cancer, run by ImmunityBio, Inc., now recruiting.
Overview
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer is a phase 2 interventional study registered as NCT06710288 by ImmunityBio, Inc., with 20 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-05. Interventions recorded: Gemcitabine, N-803, M-CENK. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCombination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Shares ImmunityBio, Nogapendekin alfa inbakicept, Gemcitabine.
- TrialN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Shares ImmunityBio, Nogapendekin alfa inbakicept.
- TrialClinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Shares ImmunityBio, Nogapendekin alfa inbakicept.
- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares ImmunityBio, Nogapendekin alfa inbakicept.
- IdeaOff-the-shelf natural killer cells to sweep up residual disease
Shares ImmunityBio, Nogapendekin alfa inbakicept.
- TrialA Study of SHR-A1811 in Subjects With Ovarian Cancer
Shares Gemcitabine, Ovarian cancer.
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Gemcitabine, Ovarian cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or
Shares Gemcitabine, Ovarian cancer.